Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases

Kychygina, Anna; Cassagne, Myriam; Tauber, M.; Galiacy, Stéphane; Paul, C.; Fournié, Pierre; Simon, Michel

doi:10.1007/s12016-022-08934-0

Cited by 37 publications

(26 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 Samira Jeimy, et al reported a case who developed amyopathic dermatomyositis associated with omalizumab therapy for steroid‐refractory severe asthma. 10 Besides, Dupilumab‐associated arthralgia and ophthalmic complications (e.g., dry eyes, conjunctivitis, blepharitis, keratitis, and ocular pruritus) were respectively reported in aspirin‐exacerbated respiratory disease and allergic diseases 11 , 12 .…”

Section: Figurementioning

confidence: 99%

Adverse events for biologics in patients with CRSwNP: A meta‐analysis

Shen

Hong

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common and complex inflammatory disorder in the upper airway. Type 2 inflammation affects the severity of CRSwNP and recurrence of polyps, determining the pharmacotherapy and extent of surgery, also associated with asthma comorbidity. 1 Over the past decade, biologics targeting the biomarkers of type 2 immune reaction ----IL-4, IL-5, and IgE, have been applied to CRSwNP in phase 2 or 3 clinical trials and emerged as an effective treatment option. However, until now, the safety of these biologics has not been systematically analyzed.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Figurementioning

confidence: 99%

Adverse events for biologics in patients with CRSwNP: A meta‐analysis

Shen

Hong

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

show abstract

“…The effect of dupilumab in AA is controversial 32 . Indeed, contradicting information has been published about AA in dupilumab‐treated patients with AD.…”

Section: Discussionmentioning

confidence: 99%

Dupilumab‐associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study

Napolitano

Fabbrocini

Patruno

2023

The Journal of Dermatology

View full text Add to dashboard Cite

Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL‐13, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged ≥6 years, adolescents, and adults. Both clinical trials and real‐life data demonstrate its efficacy and safety. However, some cutaneous adverse events (cAEs) have been observed during real‐world experiences. The authors’ aim was to analyze the spectrum of cAEs in patients receiving dupilumab for the treatment of AD in a real‐world setting. A retrospective review of electronic medical records was conducted for 916 patients (475 males and 541 females; mean age, 50.23 ± 19.66 years [range, 18–91 years]) who had received dupilumab for a minimum of 1 month for the treatment of AD from December 2018 to November 2022 at the Department of Dermatology of University Federico II of Naples (Italy). The mean duration of dupilumab treatment was 27.31 ± 21.26 months. A total of 148 of 916 (16.15%) (90 males; mean age, 50.91 ± 15.34 years) patients reported other cAEs apart of AD flare; namely, facial redness (82 of 916; 8.95%), psoriasis (39 of 916; 4.25%), alopecia areata (11 of 916; 1.2%), skin peeling (11 of 916; 1.2%), parapsoriasis (three of 916; 0.32%), and vitiligo (two of 916; 0.21%). Thirty‐one of 916 (3.38%) patients discontinued dupilumab because of cAEs (18 of 916; 1.96%) for facial redness, 10 of 916 (1.09%) for psoriasis, and three of 916 (0.32%) for parapsoriasis. In our population, most of the cAEs were mild and did not require discontinuation of dupilumab. These findings would enable dermatologists understand the cutaneous side effects of dupilumab better, resulting in improved treatment plan decisions in clinical practice.

show abstract

“…Among the CRSwNP population with adverse effects to dupilumab, women and the elderly are at higher risk of developing adverse events, while male patients are more likely to have severe adverse events [43]. In addition to injection site reaction, nasopharyngitis, headaches, epistaxis, hypereosinophilia, ophthalmic complications, head and neck dermatitis, alopecia areata, and arthritis are occasionally seen during the use of dupilumab [44, 45].…”

Section: Adverse Effects Of Biological Agentsmentioning

confidence: 99%

Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai)

Hong¹,

Chen²,

Yang³

et al. 2023

ORL

View full text Add to dashboard Cite

Background: Chronic rhinosinusitis (CRS) is a common inflammatory disease in otolaryngology, mainly manifested as nasal congestion, nasal discharge, facial pain/pressure, and smell disorder. CRS with nasal polyps (CRSwNP), an important phenotype of CRS, has a high recurrence rate even after receiving corticosteroids and/or functional endoscopic sinus surgery. In recent years, clinicians have focused on the application of biological agents in CRSwNP. However, it has not reached a consensus on the timing and selection of biologics for the treatment of CRS so far. Summary: We reviewed the previous studies of biologics in CRS and summarized the indications, contraindications, efficacy assessment, prognosis, and adverse effects of biologics. Also, we evaluated the treatment response and adverse reactions of dupilumab, omalizumab, and mepolizumab in the management of CRS and made recommendations. Key Messages: Dupilumab, omalizumab, and mepolizumab have been approved for the treatment of CRSwNP by the US Food and Drug Administration. Type 2 and eosinophilic inflammation, need for systemic steroids or contraindication to systemic steroids, significantly impaired quality of life, anosmia, and comorbid asthma are required for the use of biologics. Based on current evidence, dupilumab has the prominent advantage in improving quality of life and reducing the risk of comorbid asthma in CRSwNP among the approved monoclonal antibodies. Most patients tolerate biological agents well in general with few major or severe adverse effects. Biologics have provided more options for severe uncontrolled CRSwNP patients or patients who refuse to have surgery. In the future, more novel biologics will be assessed in high-quality clinical trials and applied clinically.

show abstract

Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases

Cited by 37 publications

References 118 publications

Adverse events for biologics in patients with CRSwNP: A meta‐analysis

Adverse events for biologics in patients with CRSwNP: A meta‐analysis

Dupilumab‐associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study

Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai)

Contact Info

Product

Resources

About